iHuman
4 hedge funds and large institutions have $8.03M invested in iHuman in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 4 closing their positions.
1% more capital invested
Capital invested by funds: $7.97M → $8.03M (+$54.7K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.04% less ownership
Funds ownership: 5% → 4.96% (-0.04%)
50% less funds holding
Funds holding: 8 → 4 (-4)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$6.66K |
| 2 |
State Street
Boston,
Massachusetts
|
+$5.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$43.8K |
| 2 |
Renaissance Technologies
New York
|
-$34K |
| 3 |
Morgan Stanley
New York
|
-$10.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$547 |
IH Hedge Fund Activity: Q4 2023 in Review
4 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in iHuman (IH) for Q4 2023, worth a combined $8.03M — up 0.69% from $7.97M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IH and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was RhumbLine Advisers, adding an estimated $6.66K. The largest seller was Citadel Advisors, exiting entirely with an estimated $43.8K sold.
- 4 institutional investors held iHuman (IH) as of Q4 2023, down from 8 in Q3 2023.
- Funds reported $8.03M of iHuman stock for Q4 2023, up 0.69% quarter-over-quarter.
- 0 funds opened new iHuman positions in Q4 2023 and 4 closed out, a net change of -4 holders.
- The largest iHuman buyer in Q4 2023 was RhumbLine Advisers, an estimated $6.66K added.
- The largest iHuman seller in Q4 2023 was Citadel Advisors, an estimated $43.8K sold.
Based on aggregated 13F filings for Q4 2023.